RCT | Doxorubicin alone vs. doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma.
20 Jul, 2022 | 11:36h | UTCDoxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)